Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Intensity Therapeutics Inc's Business Segments
Intensity Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Reportable0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Reportable0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | - | - |
Description of Intensity Therapeutics Inc
Intensity Therapeutics Inc. is a biotechnology company headquartered in Westport, Connecticut. The company is focused on developing and commercializing novel cancer therapeutics that harness the body's immune system to fight cancer.
Founded in 2012, Intensity Therapeutics employs a unique and innovative approach to cancer treatment called IntraTumoral Cancer Immunotherapy (ITCI). This approach involves directly injecting proprietary drug formulations called INT230 into tumors, with the aim of initiating a localized immune response against cancer cells.
INT230 is a novel drug compound that consists of active pharmaceutical ingredients (APIs) in a water-based solution. It is designed to cause targeted destruction of tumor cells while also stimulating an immune response. The drug is administered through intratumoral injection, allowing for strong local effects without impacting healthy surrounding tissue.
The company's technology platform leverages the body's natural immune response to fight cancer. INT230 consists of potent anticancer agents that directly kill tumor cells, leading to the release of tumor-specific antigens. This triggers an immune response, leading to the activation of antigen-presenting cells, T cells, and other immune cells that together work to attack the tumor.
Intensity Therapeutics has conducted preclinical studies on various cancer types, including solid tumors, demonstrating the potential of their technology. The company has also initiated clinical trials to evaluate the safety and efficacy of INT230 in patients with different cancer types.
One significant advantage of Intensity Therapeutics' approach is its potential to treat both primary tumors and metastatic lesions. The localized injection of INT230 allows for direct treatment of the tumor site, including both visible and non-visible lesions, offering a potential solution in cases where surgical removal or radiation therapy is not feasible.
The company has a strong focus on research and development, continuously working to innovate and improve their drug formulations. Their team of scientists and researchers collaborate closely with academic institutions, clinical experts, and regulatory authorities to advance their technology and expand their understanding of intratumoral immunotherapy.
Intensity Therapeutics also places great emphasis on collaboration and partnership. They actively seek collaborations with other biopharmaceutical companies, cancer centers, and academic institutions to accelerate the development and commercialization of their products.
Overall, Intensity Therapeutics Inc. is a pioneering biotechnology company that is revolutionizing cancer treatment through its unique intratumoral immunotherapy approach. With its novel drug formulations and promising clinical results, the company has the potential to significantly impact the field of oncology and provide new, effective treatment options for cancer patients.
Founded in 2012, Intensity Therapeutics employs a unique and innovative approach to cancer treatment called IntraTumoral Cancer Immunotherapy (ITCI). This approach involves directly injecting proprietary drug formulations called INT230 into tumors, with the aim of initiating a localized immune response against cancer cells.
INT230 is a novel drug compound that consists of active pharmaceutical ingredients (APIs) in a water-based solution. It is designed to cause targeted destruction of tumor cells while also stimulating an immune response. The drug is administered through intratumoral injection, allowing for strong local effects without impacting healthy surrounding tissue.
The company's technology platform leverages the body's natural immune response to fight cancer. INT230 consists of potent anticancer agents that directly kill tumor cells, leading to the release of tumor-specific antigens. This triggers an immune response, leading to the activation of antigen-presenting cells, T cells, and other immune cells that together work to attack the tumor.
Intensity Therapeutics has conducted preclinical studies on various cancer types, including solid tumors, demonstrating the potential of their technology. The company has also initiated clinical trials to evaluate the safety and efficacy of INT230 in patients with different cancer types.
One significant advantage of Intensity Therapeutics' approach is its potential to treat both primary tumors and metastatic lesions. The localized injection of INT230 allows for direct treatment of the tumor site, including both visible and non-visible lesions, offering a potential solution in cases where surgical removal or radiation therapy is not feasible.
The company has a strong focus on research and development, continuously working to innovate and improve their drug formulations. Their team of scientists and researchers collaborate closely with academic institutions, clinical experts, and regulatory authorities to advance their technology and expand their understanding of intratumoral immunotherapy.
Intensity Therapeutics also places great emphasis on collaboration and partnership. They actively seek collaborations with other biopharmaceutical companies, cancer centers, and academic institutions to accelerate the development and commercialization of their products.
Overall, Intensity Therapeutics Inc. is a pioneering biotechnology company that is revolutionizing cancer treatment through its unique intratumoral immunotherapy approach. With its novel drug formulations and promising clinical results, the company has the potential to significantly impact the field of oncology and provide new, effective treatment options for cancer patients.
Intensity Therapeutics Inc. is a biotechnology company dedicated to developing innovative therapeutics aimed at improving the treatment outcomes for cancer patients. The company specializes in the segments of oncology and immuno-oncology, focusing on the design and delivery of groundbreaking therapies tailored to address the complexities of various cancer types, particularly solid tumors.
Segments
1. Oncology:
The primary segment in which Intensity Therapeutics operates is oncology. This domain is concerned with the comprehensive aspects of cancer, including its understanding, diagnosis, and treatment. The company leverages a deep knowledge of cancer biology and the tumor microenvironment to develop therapies that not only target cancer cells directly but also aim to engage the immune system against tumors.
2. Immuno-Oncology:
In addition to traditional oncology, the company emphasizes immuno-oncology, which is the branch of oncology that involves stimulating the body’s immune system to fight cancer. By developing immunotherapeutic approaches, Intensity Therapeutics seeks to harness the body’s own defenses and enhance the effectiveness of existing cancer treatments.
Products and Services
1. INT230-6:
INT230-6 is the flagship product of Intensity Therapeutics. It is a proprietary drug candidate that combines a potent chemotherapy agent, cisplatin, with a specialized liposomal delivery system. This formulation is designed for intratumoral injection, allowing for direct administration into solid tumors. The purpose of this approach is to achieve a high concentration of the drug at the site of the tumor while minimizing systemic exposure, thereby reducing side effects typically seen with chemotherapy.
- Mechanism of Action: By encapsulating cisplatin in a liposomal carrier, INT230-6 enhances the drugs stability, distribution, and retention within the tumor. This method not only optimizes anti-cancer efficacy but also aims to engage the immune response to the tumor, transforming the immunogenic profile of the cancer.
2. Drug Discovery:
Intensity Therapeutics is committed to an innovative drug discovery process that utilizes its expertise in various scientific areas including immunotherapy and nanoparticle technology. The companys strategy involves screening new chemical entities and formulations to identify candidates that can effectively target cancer cells while overcoming the limitations of existing medications.
- Focus on Novel Chemistries: Through a focus on novel chemistries, Intensity seeks to develop newly formulated compounds that enhance drug delivery and efficacy against challenging tumor types.
3. Preclinical Studies:
Prior to entering clinical trials, Intensity conducts rigorous preclinical studies to ensure the safety and efficacy of its drug candidates. These studies are vital for assessing various parameters, including:
- Tumor-Inhibiting Properties: Evaluating how well potential therapies can suppress tumor growth.
- Biodistribution: Understanding how and where the drug distributes in the body post-administration.
- Toxicity Profiles: Identifying any adverse effects that could arise from treatments, thereby safeguarding patient health as they progress into clinical studies.
4. Clinical Trials:
The clinical trial phase is crucial for verifying the effectiveness and safety of drug candidates. Intensity Therapeutics actively conducts these trials with a focus on:
- Dosing and Regimens: Determining the optimal dosages and treatment schedules that maximize therapeutic outcomes.
- Monitoring Safety: Closely observing side effects and overall patient health to ensure the risk-benefit balance is maintained.
5. Collaborations:
Recognizing the importance of collaboration in the biotechnology sector, Intensity Therapeutics partners with academic institutions, research organizations, and other pharmaceutical companies. These collaborations help to:
- Accelerate Development: Sharing resources and expertise to expedite the development timeline of promising therapies.
- Expand the Pipeline: Collaborative efforts can lead to the discovery of new treatments and the exploration of diverse treatment modalities.
Conclusion
In summary, Intensity Therapeutics Inc. operates primarily within the oncology and immuno-oncology sectors, centering its efforts on the development of INT230-6 and fostering innovation through drug discovery, preclinical and clinical studies, and strategic collaborations. By utilizing cutting-edge science and technology, the company aims to reshape cancer treatment paradigms and significantly enhance patient outcomes in the fight against cancer.
Segments
1. Oncology:
The primary segment in which Intensity Therapeutics operates is oncology. This domain is concerned with the comprehensive aspects of cancer, including its understanding, diagnosis, and treatment. The company leverages a deep knowledge of cancer biology and the tumor microenvironment to develop therapies that not only target cancer cells directly but also aim to engage the immune system against tumors.
2. Immuno-Oncology:
In addition to traditional oncology, the company emphasizes immuno-oncology, which is the branch of oncology that involves stimulating the body’s immune system to fight cancer. By developing immunotherapeutic approaches, Intensity Therapeutics seeks to harness the body’s own defenses and enhance the effectiveness of existing cancer treatments.
Products and Services
1. INT230-6:
INT230-6 is the flagship product of Intensity Therapeutics. It is a proprietary drug candidate that combines a potent chemotherapy agent, cisplatin, with a specialized liposomal delivery system. This formulation is designed for intratumoral injection, allowing for direct administration into solid tumors. The purpose of this approach is to achieve a high concentration of the drug at the site of the tumor while minimizing systemic exposure, thereby reducing side effects typically seen with chemotherapy.
- Mechanism of Action: By encapsulating cisplatin in a liposomal carrier, INT230-6 enhances the drugs stability, distribution, and retention within the tumor. This method not only optimizes anti-cancer efficacy but also aims to engage the immune response to the tumor, transforming the immunogenic profile of the cancer.
2. Drug Discovery:
Intensity Therapeutics is committed to an innovative drug discovery process that utilizes its expertise in various scientific areas including immunotherapy and nanoparticle technology. The companys strategy involves screening new chemical entities and formulations to identify candidates that can effectively target cancer cells while overcoming the limitations of existing medications.
- Focus on Novel Chemistries: Through a focus on novel chemistries, Intensity seeks to develop newly formulated compounds that enhance drug delivery and efficacy against challenging tumor types.
3. Preclinical Studies:
Prior to entering clinical trials, Intensity conducts rigorous preclinical studies to ensure the safety and efficacy of its drug candidates. These studies are vital for assessing various parameters, including:
- Tumor-Inhibiting Properties: Evaluating how well potential therapies can suppress tumor growth.
- Biodistribution: Understanding how and where the drug distributes in the body post-administration.
- Toxicity Profiles: Identifying any adverse effects that could arise from treatments, thereby safeguarding patient health as they progress into clinical studies.
4. Clinical Trials:
The clinical trial phase is crucial for verifying the effectiveness and safety of drug candidates. Intensity Therapeutics actively conducts these trials with a focus on:
- Dosing and Regimens: Determining the optimal dosages and treatment schedules that maximize therapeutic outcomes.
- Monitoring Safety: Closely observing side effects and overall patient health to ensure the risk-benefit balance is maintained.
5. Collaborations:
Recognizing the importance of collaboration in the biotechnology sector, Intensity Therapeutics partners with academic institutions, research organizations, and other pharmaceutical companies. These collaborations help to:
- Accelerate Development: Sharing resources and expertise to expedite the development timeline of promising therapies.
- Expand the Pipeline: Collaborative efforts can lead to the discovery of new treatments and the exploration of diverse treatment modalities.
Conclusion
In summary, Intensity Therapeutics Inc. operates primarily within the oncology and immuno-oncology sectors, centering its efforts on the development of INT230-6 and fostering innovation through drug discovery, preclinical and clinical studies, and strategic collaborations. By utilizing cutting-edge science and technology, the company aims to reshape cancer treatment paradigms and significantly enhance patient outcomes in the fight against cancer.